Business Context and Reporting Period
Company: Oragenics, Inc. (OGEN)
Filing Type: Form 8-K (Current Report)
Date of Report: May 8, 2020
Reporting Period: The filing updates the company's business description and risk factors following a material transaction completed on May 1, 2020.
On May 1, 2020, Oragenics completed the acquisition of Noachis Terra Inc., a privately-held Delaware corporation. Noachis Terra is now a wholly-owned subsidiary dedicated to the development and commercialization of TerraCoV2, a vaccine candidate targeting the novel SARS-CoV-2 virus (COVID-19). The acquisition was executed via a Stock Purchase Agreement with Mr. Joseph Hernandez, the sole shareholder of Noachis Terra.
Key Financial Metrics and Capital Structure
Note: This Form 8-K does not contain audited financial statements for a specific fiscal period. The following data points are derived from the Risk Factors section referencing the most recent audited data (December 31, 2019) and the terms of the recent acquisition.
- Accumulated Deficit: Approximately $127.4 million as of December 31, 2019.
- Net Losses: Approximately $15.6 million for the year ended December 31, 2019, and $9.9 million for 2018.
- Liquidity Outlook: Management states that current cash, cash equivalents, and short-term investments are not sufficient to sustain operations beyond the end of the first quarter of 2021.
- Acquisition Consideration (Noachis Terra):
- Cash: Approximately $1,925,000.
- Equity: 9,200,000 restricted shares of Oragenics common stock.
- Warrants: Warrants to purchase 9,200,000 shares of common stock (exercisability subject to shareholder approval and specific milestones).
- Outstanding Equity (Post-Acquisition): Approximately 55,324,803 shares of common stock outstanding.
- Preferred Stock: Outstanding Series A, B, and C preferred stock with liquidation preferences senior to common stock. Series C carries a 20% annual dividend payable in additional shares.
Material Changes vs. Prior Period
- Strategic Pivot: The company has shifted significant focus to vaccine development following the acquisition of Noachis Terra, entering a sector in which it previously had little to no experience.
- Product Portfolio Expansion: Addition of the TerraCoV2 vaccine candidate (Pre-clinical stage) to the existing pipeline of AG013 (Oral Mucositis) and OG716 (Antibiotic).
- Intellectual Property: Acquisition of a worldwide, nonexclusive license from the National Institute of Allergy and Infectious Diseases (NIAID) regarding prefusion coronavirus spike proteins for vaccine development.
- Ownership Structure: Significant dilution of existing shareholders; the former sole shareholder of Noachis Terra now holds approximately 16.63% of the company's common stock (excluding warrants).
Guidance, Outlook, and Risks
Management Commentary and Outlook
- TerraCoV2 Timeline: Subject to funding, the company expects to file an Investigational New Drug (IND) application with the FDA in Q4 2020 and initiate Phase 1 clinical trials by the end of 2020 or early 2021.
- Funding Needs: The company explicitly states it will need to raise additional capital to fund the development of TerraCoV2, AG013, and OG716. It is currently seeking funding from government agencies (e.g., BARDA) and private markets.
- AG013 Status: Phase 2 clinical trial for oral mucositis treatment (AG013) was completed in 2019. Top-line results announced in April 2020 did not demonstrate statistical significance on the primary endpoint, though the drug was found to be safe. Further analysis of sub-populations is pending.
Material Risks and Contingencies
- Going Concern: The company's auditor has previously expressed substantial doubt about its ability to continue as a going concern. Without additional financing, the company may be unable to remain operational.
- Regulatory Uncertainty: No vaccine for SARS-CoV-2 has been approved by any regulatory authority. Development timelines are subject to FDA review, clinical trial results, and the evolving nature of the pandemic.
- License Obligations: The NIAID license requires the company to manufacture products substantially in the United States and meet specific commercial development benchmarks. Failure to comply could result in termination of the license.
- COVID-19 Impact: The pandemic poses risks to clinical trial enrollment, supply chains, and the ability of third-party manufacturers and regulators to operate normally.
Investor Verification Checklist
- Cash Runway: Verify the exact amount of cash and cash equivalents available as of the filing date and the specific timeline for the next capital raise.
- BARDA Application Status: Confirm the current status of the pending application for Biomedical Advanced Research and Development Authority (BARDA) funding.
- AG013 Data Analysis: Review the detailed analysis of the Phase 2 clinical trial results for AG013 to determine if any sub-populations showed efficacy.
- Warrant Exercisability: Monitor the timeline for shareholder approval required to make the 9.2 million warrants issued to the Noachis Terra seller exercisable.
- Preferred Stock Dilution: Assess the impact of the 20% dividend on Series C Preferred Stock and the conversion terms of Series A and B on future equity dilution.